In a patient with chronic liver disease and a platelet count of 25 × 10³/µL, what is the role of romiplostim?

Romiplostim is NOT recommended for chronic liver disease-related thrombocytopenia

Romiplostim is FDA-approved only for immune thrombocytopenia (ITP), not for chronic liver disease (CLD)-associated thrombocytopenia. 1 For your patient with CLD and platelets of 25,000/µL, the appropriate FDA-approved thrombopoietin receptor agonists are avatrombopag or lusutrombopag—but only if a specific invasive procedure is planned.

Key Clinical Guidance for CLD with Severe Thrombocytopenia

When TPO Agonists Are Appropriate in CLD

The 2021 AASLD guidelines are explicit: routine use of TPO receptor agonists to prevent procedure-related bleeding cannot be recommended because clinical trials showed no statistical difference in actual bleeding events between treatment and placebo groups, despite achieving higher platelet counts. 2

The FDA-approved agents for CLD are:

• Avatrombopag (oral, 2-8 day course before procedure)
• Lusutrombopag (oral, 2-8 day course before procedure)

These are indicated specifically for patients with CLD scheduled to undergo a procedure, requiring 9-14 days of treatment before the intervention. 3

Critical Threshold Guidance

For a platelet count of 25,000/µL in CLD:

• Low-risk procedures (paracentesis, thoracentesis, EGD with banding): Proceed without prophylactic platelet correction 2, 4

• High-risk procedures where local hemostasis is impossible:

  • Platelet count 20-50 × 10⁹/L: Consider TPO agonists or platelet transfusion on case-by-case basis 5
  • Platelet count <20 × 10⁹/L: Should consider intervention on case-by-case basis 5

The 2022 EASL guidelines recommend against routine correction when platelet count is >50 × 10⁹/L or when bleeding can be treated by local hemostasis. 5

Why Not Romiplostim for CLD?

1. Wrong indication: Romiplostim is approved for ITP, not CLD-related thrombocytopenia 1

2. Different pathophysiology: In CLD, thrombocytopenia reflects portal hypertension and splenic sequestration—not immune destruction. The low platelet count is often a marker of disease severity rather than a causative bleeding risk factor 2

3. Thrombotic risk: Early studies with eltrombopag (another TPO agonist) in CLD were discontinued due to excess thrombotic events, particularly portal vein thrombosis, when targeting excessively high platelet counts 2

4. Lack of bleeding benefit: Studies show no reduction in actual bleeding events despite platelet count increases 2

The Rebalanced Hemostasis Concept

Patients with stable CLD have "rebalanced" hemostasis: decreased platelets and procoagulant factors are offset by increased factor VIII, von Willebrand factor, and reduced natural anticoagulants. 3 This creates a net effect of normal or even procoagulant hemostasis, explaining why low platelet counts don't predict bleeding as they would in other conditions.

Practical Management Algorithm

For your patient with CLD and platelets 25,000/µL:

1. No planned procedure: No intervention needed; observe clinically

2. Planned low-risk procedure: Proceed without platelet correction 2

3. Planned high-risk procedure without local hemostasis option:

   • Consider avatrombopag or lusutrombopag (start 9-14 days before procedure) 3
   • Alternative: Case-by-case decision for platelet transfusion
   • Do not use romiplostim (wrong indication)

4. Active bleeding: Manage with transfusion and hemostatic procedures as needed, not prophylactically 2

Important Caveats

• Paradoxical finding: Studies show patients receiving prophylactic platelet transfusion were MORE likely to experience bleeding, suggesting low platelets reflect portal hypertension severity rather than causing bleeding directly 2

• Child-Pugh score matters more: Progressive hepatic decompensation is a stronger predictor of bleeding than absolute platelet count 4

• Avoid volume overload: Platelet transfusions increase portal pressure and carry risks (TRALI, TACO, infections) without proven bleeding reduction 3

If you must use a TPO agonist for a planned procedure in this CLD patient, use avatrombopag or lusutrombopag—not romiplostim. Otherwise, the safest approach for most procedures is to proceed without prophylactic platelet correction, managing bleeding if it occurs rather than attempting prevention based on laboratory values alone.